revis estim expect challeng
overcom downgrad neutral
action revis forecast beyond lower
target price line reduc ep estim
downgrad chugai outperform neutral potenti upsid
less
invest overview chugai share price seem like plateau
somewhat near term partli due strong perform
within pharmaceut sector attribut number factor
includ impress chugai achiev earn growth
book gain dispos long-list drug transfer price
announc possibl compani
hit hard april round drug price cut herceptin rituxan
mainstay product japan possibl target price cut excess
current cautiou view contribut chugai
earn new hemophilia drug emicizumab roch brand name
hemlibra although drug approv launch europ
us antibody/anticanc tecentriq need time
catch exist product ono merck launch
april second-lin therapi non-smal cell lung cancer nsclc
share start appear overvalu see challeng
expect chugai overcom still expect progress translat
posit beyond
catalysts/risk near term highlight valu quarterli
emicizumab export roch domest tecentriq sale chugai
januari account includ entir amount long-list drug
dispos gain discuss investor awar
fluctuat result slate april longer term
highlight progress develop bispecif antibodi
valuat target price base forward price-to-earnings
previous appli ep estim
valuat metric
chang tp
number share mn
price month
outperform neutral
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price feb upsid rate outperform neutral target price analyst
profit tax
issuanc retir stock
net chang cash
number share mn
figur comparison chang view rate target price revis
modest stabl growth
op declin real term gain sale long-
list drug factor risk signific price cut
hit all-tim share price high sector best perform
expect stabl share price perform upsid may limit
earn contribut new product emerg
downgrad neutral
forecast compani hit hard april round drug price cut
herceptin rituxan mainstay product japan possibl target price
cut excess
take cautiou view contribut chugai earn new
hemophilia drug emicizumab roch brand name hemlibra although drug
approv launch europ us
antibody/anticanc tecentriq need time catch exist
product ono merck launch april second-lin therapi non-
share start appear overvalu revis estim
profit tax
cash equival
bone joint diseas field
compani mention price
